Peter Verhamme to Treatment Outcome
This is a "connection" page, showing publications Peter Verhamme has written about Treatment Outcome.
Connection Strength
0.128
-
Itraconazole for COVID-19: preclinical studies and a proof-of-concept randomized clinical trial. EBioMedicine. 2021 Apr; 66:103288.
Score: 0.033
-
Thrombolytic efficacy of recombinant human microplasmin in a canine model of copper coil-induced coronary artery thrombosis. J Thromb Thrombolysis. 2010 Jul; 30(1):46-54.
Score: 0.016
-
Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma. Eur Respir J. 2022 02; 59(2).
Score: 0.009
-
Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2-azithromycin trial. Trials. 2021 Feb 09; 22(1):126.
Score: 0.008
-
Rationale for azithromycin in COVID-19: an overview of existing evidence. BMJ Open Respir Res. 2021 01; 8(1).
Score: 0.008
-
A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials. 2020 Nov 27; 21(1):981.
Score: 0.008
-
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. Europace. 2018 08 01; 20(8):1231-1242.
Score: 0.007
-
Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study. Thromb Haemost. 2018 Aug; 118(8):1439-1449.
Score: 0.007
-
Management of major bleeding and outcomes in patients treated with direct oral anticoagulants: results from the START-Event registry. Intern Emerg Med. 2018 Oct; 13(7):1051-1058.
Score: 0.007
-
Targeting Coagulase Activity in Staphylococcus aureus Bacteraemia: A Randomized Controlled Single-Centre Trial of Staphylothrombin Inhibition. Thromb Haemost. 2018 05; 118(5):818-829.
Score: 0.007
-
Results of a randomized controlled pilot trial of intravascular renal denervation for management of treatment-resistant hypertension. Blood Press. 2017 12; 26(6):321-331.
Score: 0.006
-
Low-Dose and Slow-Infusion Thrombolysis for Prosthetic Valve Thrombosis After a Transcatheter Valve in the Mitral Position. JACC Cardiovasc Interv. 2017 04 10; 10(7):738-739.
Score: 0.006
-
Outcome-driven thresholds for ambulatory pulse pressure in 9938 participants recruited from 11 populations. Hypertension. 2014 Feb; 63(2):229-37.
Score: 0.005